^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Aybintio (bevacizumab biosimilar) (VEGF-A inhibitor) + Pegasys (pegylated interferon α -2a) (IFNα stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.